• EN/ES

    Orthopedics

    WebHealthNetwork : 2,378,479


  • Benefits & Savings

  • : Leukemia, Myeloid, Chronic-Phase

Leukemia, Myeloid, Chronic-Phase - 25 Studies Found

Withdrawn : Imatinib Response in Patients With Chronic Myeloid Leukemia (CML) in Function of Abl Polymorphisms
: Leukemia, Myeloid, Chronic-Phase
: 2012-07-24
Terminated : Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)
: Leukemia, Myeloid, Chronic Phase
: 2005-07-27
: Drug: Imatinib mesylate Imatinib is packaged in bottles as 100mg and 400mg tablets
Completed : Treatment With Second Generation Tyrosine Kinase Inhibitors (2G TKI) Post Imatinib Failure Survey
: Leukemia, Myeloid, Chronic-Phase (CML-CP)
: 2010-08-24
: Drug: Imatinib Drug being observed but not provided
Active, not recruiting : Pilot Study to Assess Telemonitoring of Gleevec (Imatinib Mesylate) or Tasigna (Niltinib) Therapy
: Chronic Phase CML
: 2011-10-14
:
  • Behavioral: no access to eMedonline

Active, not recruiting : Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib
: Chronic Phase Chronic Myeloid Leukemia
: 2012-05-04
:
  • Drug: Imatinib Other Names:

Not yet recruiting : A Study of Ruxolitinib in Combination With Nilotinib in Patients With Chronic Phase CML
: Leukemia, Chronic Myeloid
: 2016-11-22
:
  • Drug: Nilotinib Nilotinib 300

Active, not recruiting : A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase CML or With Ph+ Leukemias Resistant or Intolerant to Imatinib
: Leukemia
: 2008-10-21
: Drug: Dasatinib Other Name: Sprycel (BMS-354825)
Active, not recruiting : Ruxolitinib in Combination With Nilotinib in Chronic Myeloid Leukemia (CML) Patients
: Chronic Phase Chronic Myeloid Leukemia
: 2012-10-03
:
  • Drug: Nilotinib

Active, not recruiting : Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)
: Leukemia, Myelogenous, Chronic
: 2005-08-11
: Drug: Nilotinib 400 mg orally twice daily Other Name
Terminated : Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
: Leukemia, Myeloid, Chronic
: 2006-05-01
:
  • Drug: Imatinib Imatinib tablet

<<< Previous | Next >>>
Orthopedics Health
Orthopedics Health WebHealth Network Media
  • WebHealthNetwork
  • DiabetesHealthMatters
  • HeartandStrokeHealth
  • WomensHealthCareCommunity
  • AsthmaHealthCenter
  • CancerHealthCenter
  • MentalHealthHelpCenter
  • Skincarehealthcenter
  • DigestiveTractHealth
  • VaccineHealthCenter
  • PainHealthCenter
  • FightingAddictionCenter
  • ObesityHealthMatters
  • SeniorHealthcareMatters
  • BrainAndNerveCenter
  • PediatricsHealthCenter
  • RareDiseasesHealthCenter
  • Wealth Mason
  • Home Owners Circle
  • EasyInsuranceFinder
  • EduJumpStart
  • SaleSpider
  • ScoopCafe
  • SaleSpiderMedia
  • Viewpoint.World
  • TravelerBooked
  • TechNewsBytes
  • Contact Us
  • Advertising Privacy Policy

This site uses cookies for analytics and advertising. No personal information is collected.

© Orthopedics Health .

We use cookies to enhance your experience, analyze anonymized traffic, and deliver personalized content and ads. No personal information is collected. By using our website, you consent to our use of cookies and agree to our data practices as described in our Privacy Policy. To Reject, please change your browser settings.